Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | HDAC1 | Q13547 | 5/20 | 0.40 |
| ▸ | HDAC4 | P56524 | 3/20 | 0.40 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.40 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.40 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.40 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.39 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.39 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.39 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.39 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.39 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.39 |
| ▸ | CDK4 | P11802 | 1/20 | 0.39 |
| ▸ | MEF2D | Q14814 | 1/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1093253 | 1.00 | CYP3A4 (0.40) | CYP3A4MAPTHDAC1HDAC4HDAC3 | |
| SCHEMBL726717 | 0.82 | MAPT (0.49) | CYP3A4MAPTHDAC1HDAC4HDAC3 | |
| SCHEMBL726718 | 0.82 | MAPT (0.49) | CYP3A4MAPTHDAC1HDAC4HDAC3 | |
| SCHEMBL1093251 | 0.81 | CYP3A4 (0.40) | CYP3A4MAPTHDAC1HDAC4HDAC3 | |
| SCHEMBL726647 | 0.81 | CYP3A4 (0.40) | CYP3A4MAPTHDAC1HDAC4HDAC3 | |
| SCHEMBL726425 | 0.81 | MAPT (0.47) | CYP3A4MAPTHDAC1HDAC4HDAC3 | |
| SCHEMBL726426 | 0.81 | MAPT (0.47) | CYP3A4MAPTHDAC1HDAC4HDAC3 | |
| SCHEMBL726914 | 0.77 | — | — | |
| SCHEMBL726913 | 0.77 | — | — | |
| SCHEMBL1254077 | 0.75 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1560584-B1 | FAB I INHIBITORS | AFFINIUM PHARM INC (CA) | 2009-01-14 | — | — | EP | claimed |
| US-7049310-B2 | Fab I inhibitors | AFFINIUM PHARMACEUTICALS, INC. (CA) | 2006-05-23 | — | — | US | claimed |
| EP-1560584-A4 | FAB I INHIBITORS | AFFINIUM PHARM INC (CA) | 2005-10-12 | — | — | EP | claimed |
| EP-1560584-A2 | FAB I INHIBITORS | Affinium Pharmaceuticals, Inc. (CA) | 2005-08-10 | — | — | EP | claimed |
| WO-2003088897-A2 | FAB I INHIBITORS | AFFINIUM PHARMACEUTICALS, INC. (CA) | 2003-10-30 | — | — | WO | claimed |
| US-20130281442-A1 | Compounds for Treatment of Bovine Mastitis | DEBIOPHARM INTERNATIONAL SA (CH) | 2013-10-24 | — | — | US | disclosed |
| EP-2579863-A2 | COMPOUNDS FOR TREATMENT OF BOVINE MASTITIS | Affinium Pharmaceuticals, Inc. (CA) | 2013-04-17 | — | — | EP | disclosed |
| US-8153652-B2 | Fab I inhibitors | AFFINIUM PHARMACEUTICALS, INC. (CA) | 2012-04-10 | — | — | US | disclosed |
| US-20120010127-A1 | Compositions Comprising Multiple Bioactive Agents, and Methods of Using the Same | BERMAN JUDD M (CA) | 2012-01-12 | — | — | US | disclosed |
| WO-2011156811-A2 | COMPOUNDS FOR TREATMENT OF BOVINE MASTITIS | AFFINIUM PHARMACEUTICALS, INC. (CA) | 2011-12-15 | — | — | WO | disclosed |
| US-20110098277-A1 | Fab I Inhibitors | DEBIOPHARM INTERNATIONAL SA (CH) | 2011-04-28 | — | — | US | disclosed |
| US-7879872-B2 | comprising (E)-N-methyl-N-(3-methylbenzofuran-2-ylmethyl)-3-(7-oxo-5,6,7,8-tetrahydro-1,8-naphthyridin-3-yl)acrylamide or pharmaceutically acceptable salts thereof; and gentamicin; wherein combination has an fractional inhibitory coconcentration index value of 0.3 against S. aureus 29213 | AFFINIUM PHARMACEUTICALS, INC. (CA) | 2011-02-01 | — | — | US | disclosed |
| US-20060116394-A1 | Fab I inhibitors | DEBIOPHARM INTERNATIONAL SA (CH) | 2006-06-01 | — | — | US | disclosed |
| US-7049310-B2 | Fab I inhibitors | AFFINIUM PHARMACEUTICALS, INC. (CA) | 2006-05-23 | — | — | US | disclosed |
| EP-1608377-A2 | PHARMACEUTICAL COMPOSITIONS COMPRISING INHIBITORS OF FAB I AND FURTHER ANTIBIOTICS | Affinium Pharmaceuticals, Inc. (CA) | 2005-12-28 | — | — | EP | disclosed |
| EP-1560584-A4 | FAB I INHIBITORS | AFFINIUM PHARM INC (CA) | 2005-10-12 | — | — | EP | disclosed |
| EP-1560584-A2 | FAB I INHIBITORS | Affinium Pharmaceuticals, Inc. (CA) | 2005-08-10 | — | — | EP | disclosed |
| WO-2004082586-A2 | PHAMACEUTICAL COMPOSITIONS COMPRISING INHIBITORS OF FAB I AND FURTHER ANTIBIOTICS | AFFINIUM PHARMACEUTICALS, INC. (US) | 2004-09-30 | — | — | WO | disclosed |
| US-20040147580-A1 | Fab I inhibitors | DEBIOPHARM INTERNATIONAL SA (CH) | 2004-07-29 | — | — | US | disclosed |
| WO-2003088897-A2 | FAB I INHIBITORS | AFFINIUM PHARMACEUTICALS, INC. (CA) | 2003-10-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130281442-A1 | Compounds for Treatment of Bovine Mastitis | LPO, MPO, MMP8 | CYP3A4 3624/4885MAPT 2755/4885HDAC1 488/4885 |
| US-20060116394-A1 | Fab I inhibitors | SERPINB1, TMBIM6, GDI2 | CYP3A4 3590/4885MAPT 4105/4885HDAC1 97/4885 |
| US-20120010127-A1 | Compositions Comprising Multiple Bioactive Agents, and Methods of Using the Same | DBI, SERPINB1, CTSF | CYP3A4 4356/4885MAPT 3883/4885HDAC1 82/4885 |
| US-20040147580-A1 | Fab I inhibitors | SERPINB1, TMBIM6, GDI1 | CYP3A4 3447/4885MAPT 4135/4885HDAC1 77/4885 |
| US-20110098277-A1 | Fab I Inhibitors | SERPINB1, TMBIM6, GDI2 | CYP3A4 3590/4885MAPT 4105/4885HDAC1 97/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.